Objective The efficacy of combined treatment consisting of enalapril and folic acid (FA) was compared to that of enalapril alone in reducing the serum uric acid (UA) levels in adult hypertensive patients in China. Methods Patients with mild to moderate hypertension (n=480) were randomly assigned to one of three treatment groups: (1) 10 mg enalapril (control group), (2) 10 mg enalapril plus 0.4 mg FA (low-FA group) or (3) 10 mg enalapril plus 0.8 mg FA (high-FA group) daily for eight weeks. The primary outcome was the UA ratio (week 8 UA: baseline UA). Results The final analysis included 450 patients (43.1% men, 27-75 years of age). An adjusted multivariable regression analysis revealed no significant differences in the UA ratio between the three groups after eight weeks of treatment. In the subgroup analysis stratified according to the baseline UA level, the high-FA group demonstrated a significantly greater UA-lowering response among the patients with an elevated baseline UA concentration (UA ! 310 μmol/L) [median UA ratio (25th percentile, 75th percentile): 0.94 (0.83, 1.01)], compared with that observed in the control group [0.97 (0.90, 1.00), p=0.025]. Similar results were found in the participants with baseline hyperuricemia (HUA; UA: men >420 μmol/L, women >350 μmol/L). Conclusion In this sample of adult hypertensive patients, the administration of a daily dose of 10 mg of enalapril combined with 0.8 mg of FA had a greater beneficial effect on the serum UA levels than did that of 10 mg of enalapril alone in patients with either an elevated UA concentration or HUA.
Introduction
The global prevalence and incidence of hyperuricemia (HUA) have both risen steadily over the past 40 years (1) in parallel with the rising prevalence of other chronic diseases, including hypertension and cardiovascular disease. Uric acid (UA) is the final product of purine metabolism in humans. It is well established that elevated serum UA (or HUA) is the cause of gout. In addition, HUA, or an even mildly elevated UA level within the normal range (>310-330 μmol/L), can significantly increase the risk of stroke, stroke-related mortality (2) and coronary heart disease events (3) . Hypertension may provide a link between elevated UA and stroke. A growing body of evidence indicates that HUA and hypertension often co-exist and appear to feed into each other. HUA is associated with an increased risk of incident hypertension that is independent of traditional risk factors (4, 5) . On the other hand, the use of diuretics or aspirin in hypertensive patients may increase the serum UA levels (6) . In light of the bi-directional relationship between hypertension and HUA, there is a need to develop therapies to simultaneously control hypertension and HUA, which may be more effective in preventing HUA and gout in hypertensive patients.
Conventional HUA therapies aim at either reducing UA production using xanthine oxidase (XO) inhibitors, such as allopurinol, or increasing renal UA excretion with drugs, such as benzene bromide malone and probenecid. While these agents can effectively lower the serum UA levels, they do have a number of side effects, including allergic reactions, liver damage, kidney damage, bone marrow suppression and gastrointestinal symptoms (7) . As a result, there is a clear need to explore safe and effective therapeutic options.
Among the commonly used antihypertensive agents, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may improve the renal function and protect against the development of HUA (8) . However, ACE inhibitors alone are inadequate for controlling HUA, although the addition of folic acid may be beneficial, in particular among Chinese hypertensive patients who are known to have a high prevalence of elevated homocysteine (Hcy) (9, 10) .
An elevated Hcy level is an established risk factor for hypertension (11) and cardiovascular disease (12, 13) . In addition, elevated Hcy and the methylenetetrahydrofolate reductase (MTHFR) 677T allele have been linked to HUA (14) (15) (16) . One possible mechanism for this phenomenon is the decreased renal clearance of UA associated with an elevated Hcy level. In addition, the generation of adenosine originating from S-adenosyl-homocysteine, a precursor of Hcy, may constitute a link between the metabolic pathways of Hcy and UA (15) . On the other hand, in patients with the MTHFR 677TT genotype, renovascular atherosclerosis and/ or the complications of systemic vascular disease may reduce the renal clearance of UA, resulting in elevation of the serum UA level (16) . Therefore, lowering the Hcy level is likely to have a beneficial effect on the serum UA level, particularly in subjects with the MTHFR 677TT genotype. Previous studies have demonstrated that folic acid (FA) treatment can effectively lower the Hcy level (17) , and a meta-analysis showed that the optimal daily dose of FA is 0.8 mg (18) . Moreover, elevated Hcy is widespread in the Chinese population, with levels as high as 70% in hypertensive Chinese patients, due to a combination of inadequate dietary intake, the lack of grain FA fortification and a relatively high frequency of the MTHFR gene mutation (C677T) (19, 20) . A cross-sectional study in Taiwan reported an inverse association between FA intake and the blood UA level (21) .
We hypothesize that combination therapy with an ACE inhibitor and FA is a promising treatment for lowering the UA level and reducing the risk of HUA in hypertensive Chinese patients. In this multicenter, randomized, double-blind, parallel-controlled clinical trial, we investigated the effects of an ACE inhibitor (enalapril) alone vs. that used in combination with two different doses of FA on the serum UA levels after an eight-week treatment period. In addition, we explored whether the treatment effect varied according to the baseline UA level.
Materials and Methods

Participants and ethics
This was a multicenter, randomized, double-blind controlled trial of hypertensive Chinese adults (clinicaltrials.gov; identifier: NCT00520247 (10, 22) . In total, 480 patients with mild or moderate hypertension were recruited from six hospitals in different regions of China (Ha'erbin, Shanghai, Shenyang, Beijing, Xi'an and Nanjing) from September to December 2005. All six hospitals were certified as clinical pharmacology centers by the State Food and Drug Administration of China. The inclusion criteria were as follows: 1) an age between 18 and 75 years; 2) a seated systolic blood pressure (SBP) between 140 mmHg and 180 mmHg and/or seated diastolic blood pressure (DBP) between 90 mmHg and 110 mmHg; 3) consent to use a reliable method of contraception during the study among women of reproductive age; and 4) agreement to not take any other drugs that may affect blood pressure or any vitamin B supplements during the week before the start of the study. Participants were excluded if they were pregnant or planned to become pregnant during the study period, had serious diseases (cardiovascular disease, tumors, hepatic disease and so on) or expected to take other drugs that may affect blood pressure or any vitamin B supplements during the study period. This study was approved by the Ethics Committee of Peking University First Hospital, Beijing, China. The purpose and procedures of the study were carefully explained to all participants, and written informed consent was obtained from each subject.
Intervention and data collection
Eligible participants were randomly and double-blindly assigned to one of the three treatment groups: (1) enalapril tablet only (10 mg, control group); (2) enalapril-FA tablet (10 mg enalapril combined with 0.4 mg of FA, low FA group); or (3) enalapril-FA tablet (10 mg enalapril combined with 0.8 mg of FA, high FA group), once daily for eight weeks. Demographic and clinical information was obtained at baseline. Blood pressure was measured at baseline and every two weeks for a total period of eight weeks. The serum UA concentration was measured at baseline and after eight weeks of treatment.
Randomization and blinding
In order to achieve a balance among the three treatment groups, permuted-fixed block randomization with a block length of six was used. The allocation of participants was programmed at an independent statistical coordinating center, encrypted and then sent to each study center. Tablet containers were labeled with the name of the trial and the allo- cated concealment number only. Participants, care partners and all staff directly involved in the trial were blinded to the interventions during the study period. No requests were made to break the blinding protocol.
Blood sample collection and laboratory methods
After 10-12 hours of fasting, a venous blood sample was obtained from each participant. The serum and plasma samples were separated within 15 minutes of collection and analyzed within 30 minutes or stored at -80°C for a later analysis. Blood samples collected at baseline and at week 8 of the trial were used to measure the levels of UA, lipids [including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG)], glucose, Hcy and FA. The level of Hcy in the plasma was determined in duplicate using high-performance liquid chromatography. The intra-and inter-assay coefficients of variation were 3.5% and 4.2%, respectively. The serum FA level was determined using a chemiluminescent immunoassay with the Beckman Coulter ACCESS Immunoassay System (Beckman-Coulter Canada, Mississauga, Canada). The intra-and inter-assay coefficients of variation were 2.3% and 3.7%, respectively. All sample collection and testing was performed in an identical manner, following the same standard protocol.
Follow-up of the study subjects
All eligible participants were followed for a total of eight weeks. Face-to-face interviews were conducted at baseline and weeks 2, 4, 6 and 8 of the study. The subjects were asked to maintain their regular dietary habits and not to take any vitamin B supplements or any other antihypertensive medications during the entire duration of the study. On day 56, all participants were asked to return to the study center to complete the same study procedure as applied at baseline. "Lost to follow-up" defined subjects who did not complete the entire study protocol.
Outcomes
The primary outcome was the UA ratio, which was defined as the ratio of the UA concentration at week 8 to the UA concentration at baseline. Since the distribution of the UA concentration was positively skewed, the UA ratio was used to better account for the baseline UA concentration and standardize the outcome measurements across individuals.
Statistical analysis
All analyses were performed according to the principle of intention to treat. Means (SD) or medians (25th percentile, 75th percentile) and proportions were calculated for baseline characteristics according to the treatment group. The total UA, Hcy, TG and FA levels were positively skewed and thus natural log-transformed to normalize their distribution. A one-way analysis of variance for continuous variables and the chi-square test for categorical variables were applied to compare the characteristics of the study subjects among the three treatment groups. The Kruskal-Wallis rank-sum test was also used to compare the UA, Hcy, TG and FA levels among the three treatment groups. Multivariable regression models were applied to compare the ln-transformed UA ratio among different groups, with or without adjustment of the major baseline characteristics. We also performed a subgroup analysis, stratified by the baseline UA level. All p values were two-tailed, with a significance level of 0.05. Data management and all statistical analyses were carried out using the R software program, version 3.0.0 (http://www.Rproject.org/).
Results
Participant flow
The flow of participants through the study is shown in Fig. 1 . A total of 480 eligible patients with mild to moderate essential hypertension recruited from the six study centers in China were randomly assigned to one of the three treatment groups. This analysis excluded 30 individuals who were lost to follow-up or ineligible to participate in the trial (seven in the control group, 11 in the low FA group and 12 in the high FA group). Accordingly, a total of 450 participants were included in the final analysis.
Baseline data
The demographic and clinical characteristics of the study subjects in each treatment group are shown in Table 1 . Of the 450 subjects (43.1% men, 27-75 years of age), 98.7% were of Han nationality, with a mean body mass index (BMI) of 25.7 kg/m 2 . Participants in each of the three groups were well-balanced at baseline with regard to relevant demographic and clinical characteristics. Using two standards [1) UA levels 310 μmol/L (2) and 2) UA men > 420 μmol/L, women >350 μmol/L (hyperuricemia, according to Internal Medicine, Chinese, 2007)] as the cutoff, the proportion of participants with an elevated UA concentration was also well-balanced among the three treatment groups (p=0.729), as was that of the participants with HUA (p= 0.991, Table 2 ).
Outcomes and estimation
Among the total sample of the participants without HUA, we did not observe any significant differences in the UA ratio between the treatment groups after the eight-week treatment period compared with that observed at baseline. However, among the subjects with a baseline UA level of ! 310 μmol/L or HUA, the high-FA group showed a significantly greater UA-lowering response compared with the control group [as reflected by the median UA ratio (25th percentile, 75th percentile): 0.94 (0.83, 1.01) vs. 0.97 (0.90, 1.00), p= 0.025]. Similar results were observed among the participants with HUA at baseline [0.87 (0.78, 1.00) vs. 0.95 (0.87, 1.00), p=0.018; Table 3 and Fig. 2 ]. There were no differences in UA-lowering effects between the control and low-FA groups (Table 3 and Fig. 2) . All of the analyses were adjusted for the baseline UA level, study center and other relevant demographic and clinical characteristics. Our data also suggest the presence of a dose-response relationship between the treatment group and the degree of UA reduction among the subjects with higher baseline UA levels (p trend test <0.05) ( Table 3 ). In the total sample and the participants without an elevated UA concentration (UA <310 μmol/L) or HUA at baseline, there were no significant differences between the groups (Table 3 and Fig. 2 ).
This analysis excluded 30 individuals who were lost to follow-up. A sensitivity analysis showed that there were no significant differences in baseline characteristics between the excluded and included participants (data not shown).
Adverse events
Finally, there were no severe adverse events during the study period. All adverse events were mild and reversible, and the incidence of adverse events was comparable between the groups.
Discussion
To our knowledge, this is the first double-blind, randomized, controlled trial to investigate the effects of combination treatment consisting of ACE inhibitors and two commonly used physiological doses of FA (0.4 or 0.8 mg/day) on the serum UA concentrations in hypertensive patients in China. Although we did not find any differences in UA-lowering effects between the three treatment groups, we demonstrated for the first time that combination FA and enalapril therapy significantly decreases the UA levels in hypertensive patients with an elevated UA concentration (UA level ! 310 μmol/L) and HUA (men >420 μmol/L, women >350 μmol/L) at baseline. This effect appears to be dose-related, with the greatest difference observed in the high-FA group (0.8 mg). These findings may help to address the clinical and epidemiological need to develop a new regimen to simultaneously treat hypertension and reduce the risk of HUA, given that hypertension and HUA often co-exist and their prevalence is increasing worldwide, including in developing countries, such as China (23, 24) .
Our findings are biologically plausible. ACE inhibitors have traditionally been used to reduce blood pressure in hypertensive patients; however, studies have also indicated that ACE inhibitors increase the renal excretion of UA by reducing its net reabsorption in the proximal tubules (8, 25) . Furthermore, enalapril may counteract the effects of common diuretics on serum UA in hypertensive patients. However, not all previous studies support this UA-lowering effect (26, 27) .
Despite the lack of consensus regarding the mechanisms by which FA influences the UA concentration, several hypotheses have been proposed. A reduction in the serum UA level can be achieved via two methods: decreasing the production of UA by inhibiting purine breakdown or enhancing UA breakdown and subsequent excretion into the urine. FA and its derivatives may inhibit XO (28) , which converts retinol to retinoic acid and xanthines to UA, which may explain why changes in the FA concentration affect the UA concentration. In addition, studies have shown that FA is a powerful Hcy-lowering agent. For example, FA supplementation decreases the plasma Hcy concentration (29) , and a lower Hcy concentration has been reported to be associated with a lower rate of HUA (30, 31) . Therefore, FA supplementation may also reduce UA production. FA, a water-soluble B vitamin, is an important co-nutrient involved in the breakdown and metabolism of proteins (32) . In this way, it may assist with removing the UA produced in the body, preventing gout flare-ups and reducing the pain associated with gout.
The majority of research conducted to date regarding the association between FA and HUA has primarily been related to the management of gout. A cross-sectional study (21) in Taiwan investigated the effects of diet and lifestyle on the self-reported gout status and found that FA, fiber and vitamin C appear to be protective against gout. The authors also found that very high doses of supplemental FA may be beneficial in preventing gout and recurrent attacks (33) . Moreover, adding FA and eicosapentaenoic acid to the diet can assist in relieving symptoms of gouty arthritis (34) . However, other supplementation studies in humans have failed to find such an effect (35) (36) (37) . For example, in one study, oral supplementation of FA in doses up to 1,000 mg did not significantly lower the serum urate concentration, urinary urate concentration or total oxypurine excretion in participants with HUA (36) . In addition, in another study, FA supplementation (0.4 mg/day) for three months resulted in a significant increase in the UA level (37) . These contradictory findings may be due in part to small sample sizes and differences in population characteristics, for example, patients treated with or without folate supplementation. Recommendations are commonly found on websites to take multivitamin supplements containing FA in order to lower the UA levels (38); however, additional clinical trial evidence is needed to provide more definitive answers.
To date, no studies have investigated the combined effects of ACE inhibitors and FA on the UA or Hcy levels. However, previous studies have presented interesting related findings. For example, it has been reported that FA may decrease the risk of incident hypertension (39) and enhance the efficacy of antihypertensive drugs by approximately 5% (40) . Furthermore, the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS) reported a 19% reduction in the risk of cardiovascular events and total mortality with the combined use of folic acid and ACE inhibitors (41) . Based on the observation in the present study that the combination of FA and an ACE inhibitor reduces the UA concentration, we suggest that the underlying mechanism of the effects of combined FA and enalapril therapy is a simultaneous reduction in blood pressure and plasma glucose, with an increase in the folic acid concentration. As a result, the administration of FA combined with enalapril may be superior to that of FA or enalapril alone in improving the renal function and increasing renal UA excretion. Additional long-term trials are therefore warranted to evaluate this scientific hypothesis and its potential mechanisms.
The differential findings of patients with vs. without elevated UA at baseline or HUA are interesting (Table 2) . Additional research in larger samples with longer follow-up is needed to further examine the relationship between FA and the serum UA level, as well as the mechanisms underlying this relationship.
One potential limitation of the current study is the lack of a true control group that did not receive treatment; all of the participants had mild to moderate essential hypertension, which required treatment. As such, we were unable to evaluate the individual effects of FA and enalapril on UA or determine if the combined effect was additive or interactive in nature. Furthermore, we did not obtain detailed information regarding dietary intake at baseline or during the eight weeks of treatment. However, all participants were asked not to take any nutritional supplements while maintaining their regular dietary habits during the study period, and the changes in UA in the control group were quite modest (Table 2). Given that the serum UA levels differed between men and women, ideally, stratification according to sex should have been carried out in the statistical analysis. However, we were unable to perform such analyses due to the small size and instead included sex as a covariate in the multivariable analysis. Although subdivision according to the baseline serum UA level was a pre-specified exploratory analysis in this study, this investigation comprised a nonrandomized analysis of a randomized trial. Therefore, our results should be viewed as suggestive rather than providing definitive evidence of the efficacy of FA treatment in lowering the serum UA level.
Conclusion
In summary, the present results demonstrate that the administration of a daily dose of 0.8 mg FA combined with enalapril, compared to that of enalapril alone, may be beneficial in lowering the serum UA concentrations in patients with an baseline elevated UA concentration or HUA. However, further studies with a larger sample size and longer duration are needed to confirm our findings and determine the most effective dose of FA. The present findings, if confirmed in future studies, may enable medical providers to offer a safe and effective treatment alternative for controlling hypertension and lowering the UA levels in patients with mild to moderate hypertension and elevated UA or HUA.
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